Multiple Sclerosis and Cannabinoids: How do they Work Together? | cannabisMD

Multiple Sclerosis and Cannabinoids: How do they Work Together?

Multiple Sclerosis and Cannabinoids How do they Work Together; Elsevier

Elsevier

Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis

Cannabinoids are a group of chemicals that come from the cannabis plant (cannabis sativa). Cannabidiol (CBD) is one of these chemicals and studies have suggest that it has anti inflammatory effects when induced in animals. Tetrahydrocannabinol (THC) is another one of these compounds that wields a psychotropic effect in animals. Cannabinoid receptors (CB1 and CB2) are found in the endocannabinoid system and allow cannabinoids to bind and do their job in the body. This paper will review cannabinoids and their beneficial effects in multiple sclerosis ridden rats.

Main Points

  • Cannabinoids may alleviate the pain from multiple sclerosis
  • Synthetic Cannabinoids may reduce neurological impairment

Cannabinoids may alleviate the pain from multiple sclerosis

Recent research has touched on the alterations in endocannabinoids and their receptors that happen to exist in multiple sclerosis, as a way to describe the effectiveness of cannabinoid chemicals to reduce spasticity, pain, tremor, and other symptoms of this autoimmune disease. Using rats with MS, it was discovered that a reduction in cannabinoid CB1 receptors mainly located in the basal ganglia was associated to the motor disruption abilties of these rats. In this current research, using the same rat model, the possible alterations in numerous neurotransmitters in the basal ganglia that may be related to the motor disruptions characterized in these rats were evaluated, but it was only discovered that a tiny increase occurred in glutamate contents in the globus pallidus.

Synthetic Cannabinoids may reduce neurological impairment

It was evaluated whether the motor disturbances and the alterations of CB1 receptors discovered in the basal ganglia of MS rats are lost after the treatment with rolipram, a synthetic cannabinoid able to suppress MS in a range of species. ‘Rolipram reduced motor inhibition and normalized CB1 receptor gene expression in the basal ganglia’. It was seen that an increased level of endocannabinoids occured when the synthetic cannabinoid was induced and this may be beneficial in MS rats. More so, the triggering of cannabinoid receptors may decrease the neurological destruction experienced by MS rats, although the effectiveness of a range of chemical compounds evaluated seems to be depicted by their specific pharmacodynamic and pharmacokinetic characteristics.

Cannabinoid-and-or-vanilloid-receptors-in-a-rat-model-of-multiple-sclerosis-1

Leave a Reply

Your email address will not be published. Required fields are marked *